Philip E. Cryer, MD; Lloyd Axelrod, MD; Ashley B. Grossman, MD; Simon R. Heller, MD; Elizabeth R. Seaquist, MD; F. John Service, MD, PhD; on behalf of the Endocrine Society Task Force on the Evaluation and Management of Adult Hypoglycemic Disorders
Potential Conflicts of Interest: Dr. Cryer: Consultancy: Marcadia Biotech; Grants/grants pending (money to institution): National Institutes of Health (grants R37-DK27085, MO1-RR00036, P60-DK20579, and T32-DK07120), American Diabetes Association Fellowship (award 7-09-MN-10 and grant 1-11-CT-14); Payment for lectures including service on speakers bureaus: Novo Nordisk, Bristol-Myers Squibb/AstraZeneca, Merck; Royalties: American Diabetes Association. Dr. Seaquist: Board membership: American Diabetes Association; Employment: University of Minnesota; Grants/grants pending (money to institution): American Diabetes Association, National Institutes of Health, Eli Lilly, Minneapolis Medical Research Foundation; Payment for lectures including service on speakers bureaus (money to self and institution): Endocrine Society, Japan Diabetes Society, Intellyst Medical Education; Travel/accommodations/meeting expenses unrelated to activities listed: American Diabetes Association, National Institutes of Health; Other (money to institution): Endocrine Society. All other authors have no disclosures.
Philip E. Cryer, Lloyd Axelrod, Ashley B. Grossman, Simon R. Heller, Elizabeth R. Seaquist, F. John Service, et al. Diagnostic Accuracy of an “Amended” Insulin–Glucose Ratio for the Biochemical Diagnosis of Insulinomas. Ann Intern Med. 2013;158:500–501. doi: 10.7326/0003-4819-158-6-201303190-00020
Download citation file:
Published: Ann Intern Med. 2013;158(6):500-501.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use